

Barcelona, 31st January 2025

OTHER RELEVANT INFORMATION

Almirall divests Algidol[®] and out-licenses Sekisan[®]

In accordance with Securities Markets Law Almirall, S.A. (“Almirall”) announce the following:

Almirall S.A. divests Algidol[®] and out-licenses Sekisan[®] in Spain, for an upfront amount of €12 million plus unconditional future payments. This is part of the regular rotation and management of the portfolio.

Algidol[®] contains the active ingredients paracetamol, codeine, and ascorbic acid, and belongs to the group of medicines called analgesics and antipyretics (for the treatment of pain and fever).

Sekisan[®] contains the active ingredient cloperastine, a cough suppressant that inhibits the cough reflex. Sekisan[®] is a medication indicated for the treatment of non-productive forms of cough, such as irritative or nervous cough.

Sincerely,

Pablo Divasson del Fraile
Investor Relations Department
investors@almirall.com